Skip to Main Content


Skip Nav Destination

Abstract OT1-06-01: ANG1005 in leptomeningeal disease (ANGLeD) trial: A randomized, open-label, phase 3 study of ANG1005 compared with Physician's Best Choice in HER2-negative breast cancer patients with newly diagnosed leptomeningeal carcinomatosis and previously treated brain metastases

Cancer Res (2019) 79 (4_Supplement): OT1-06-01.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Tarun Kumar Patel
  • Nilanjan Adhikari
  • Sk. Abdul Amin
  • Swati Biswas
  • Tarun Jha
  • Balaram Ghosh
New Journal of Chemistry (2021) 45 (12): 5291.
  • Jozef Hanes
  • Eva Dobakova
  • Petra Majerova
Current Pharmaceutical Design (2020) 26 (13): 1448.
Close Modal

or Create an Account

Close Modal
Close Modal